Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients

Mostrar otras versiones (1)

CorrigendumNielsen SA, McDonald MB, Majmudar PA. Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients. Clinical Ophthalmology. 2013;7:149–156. The paper titled "Safety of besifloxacin ophthalmic suspension 0.6% in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nielsen SA, McDonald MB, Majmudar PA
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/62887bf5ac5044139f2938998b9defcb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:62887bf5ac5044139f2938998b9defcb
record_format dspace
spelling oai:doaj.org-article:62887bf5ac5044139f2938998b9defcb2021-12-02T02:45:37ZSafety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients1177-54671177-5483https://doaj.org/article/62887bf5ac5044139f2938998b9defcb2013-04-01T00:00:00Zhttp://www.dovepress.com/opth-38279-safety-of-besifloxacin-ophthalmic-suspensicorrigendum-a12756https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483CorrigendumNielsen SA, McDonald MB, Majmudar PA. Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients. Clinical Ophthalmology. 2013;7:149–156. The paper titled "Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients," contains an inaccurate description of the intraoperative use of medications.In the Results section it is reported that 31.8% (170/534) of besifloxacin cases and 97.0% (259/267) of moxifloxacin cases had drops applied directly to the flap interface. We have determined that ambiguity in the design of the electronic case report form resulted in all day-of-surgery drops provided to patients in the LASER suite being reported in the flap interface field. The authors have since clarified with each surgeon who reported intraoperative drug use that the drops were delivered either prior to the flap creation, or following replacement of the flap.The sentence at the top of page 152 stating: "Of note, 31.8% (170/534) of besifloxacin cases and 97.0% (259/267) of moxifloxacin cases had drops applied directly to the flap interface" should say: "Of note, 31.8% (170/534) of besifloxacin cases and 97.0% (259/267) of moxifloxacin cases had intraoperative drops applied."Read the original articleNielsen SAMcDonald MBMajmudar PADove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 725-726 (2013)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Nielsen SA
McDonald MB
Majmudar PA
Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
description CorrigendumNielsen SA, McDonald MB, Majmudar PA. Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients. Clinical Ophthalmology. 2013;7:149–156. The paper titled "Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients," contains an inaccurate description of the intraoperative use of medications.In the Results section it is reported that 31.8% (170/534) of besifloxacin cases and 97.0% (259/267) of moxifloxacin cases had drops applied directly to the flap interface. We have determined that ambiguity in the design of the electronic case report form resulted in all day-of-surgery drops provided to patients in the LASER suite being reported in the flap interface field. The authors have since clarified with each surgeon who reported intraoperative drug use that the drops were delivered either prior to the flap creation, or following replacement of the flap.The sentence at the top of page 152 stating: "Of note, 31.8% (170/534) of besifloxacin cases and 97.0% (259/267) of moxifloxacin cases had drops applied directly to the flap interface" should say: "Of note, 31.8% (170/534) of besifloxacin cases and 97.0% (259/267) of moxifloxacin cases had intraoperative drops applied."Read the original article
format article
author Nielsen SA
McDonald MB
Majmudar PA
author_facet Nielsen SA
McDonald MB
Majmudar PA
author_sort Nielsen SA
title Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
title_short Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
title_full Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
title_fullStr Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
title_full_unstemmed Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
title_sort safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-lasik patients
publisher Dove Medical Press
publishDate 2013
url https://doaj.org/article/62887bf5ac5044139f2938998b9defcb
work_keys_str_mv AT nielsensa safetyofbesifloxacinophthalmicsuspension06inrefractivesurgeryaretrospectivechartreviewofpostlasikpatients
AT mcdonaldmb safetyofbesifloxacinophthalmicsuspension06inrefractivesurgeryaretrospectivechartreviewofpostlasikpatients
AT majmudarpa safetyofbesifloxacinophthalmicsuspension06inrefractivesurgeryaretrospectivechartreviewofpostlasikpatients
_version_ 1718402164215250944

Ejemplares similares